-
1
-
-
80052723775
-
-
National Cancer Institute: Cancer Treatment (PDQ). http://www.cancer.gov/ cancertopics/pdq/treatment/colon/healthprofessional/allpages/print
-
Cancer Treatment (PDQ)
-
-
-
2
-
-
34248173883
-
Bevacizumab in combination with oxaliplatin, fluorouracil, and leucovorin (FOLFOX4) for previously treated metastatic colorectal cancer: Results from the Eastern Cooperative Oncology Group Study E3200
-
DOI 10.1200/JCO.2006.09.6305
-
Giantonio BJ, Catalano PJ, Meropol NJ, et al: Bevacizumab in combination with oxaliplatin, fluorouracil, and leucovorin (FOLFOX4) for previously treated metastatic colorectal cancer: Results from the Eastern Cooperative Oncology Group Study E3200. J Clin Oncol 25:1539-1544, 2007 (Pubitemid 46733080)
-
(2007)
Journal of Clinical Oncology
, vol.25
, Issue.12
, pp. 1539-1544
-
-
Giantonio, B.J.1
Catalano, P.J.2
Meropol, N.J.3
O'Dwyer, P.J.4
Mitchell, E.P.5
Alberts, S.R.6
Schwartz, M.A.7
Benson III, A.B.8
-
4
-
-
0027461840
-
Randomized comparison of combination chemotherapy plus supportive care with supportive care alone in patients with metastatic colorectal cancer
-
Scheithauer W, Rosen H, Kornek GV, et al: Randomized comparison of combination chemotherapy plus supportive care with supportive care alone in patients with metastatic colorectal cancer. BMJ 306:752-775, 1993
-
(1993)
BMJ
, vol.306
, pp. 752-775
-
-
Scheithauer, W.1
Rosen, H.2
Kornek, G.V.3
-
5
-
-
0034727063
-
Irinotecan plus fluorouracil and leucovorin for metastatic colorectal cancer: Irinotecan study group
-
Saltz LB, Cox JV, Blanke C, et al: Irinotecan plus fluorouracil and leucovorin for metastatic colorectal cancer: Irinotecan study group. N Engl J Med 343:905-914, 2003
-
(2003)
N Engl J Med
, vol.343
, pp. 905-914
-
-
Saltz, L.B.1
Cox, J.V.2
Blanke, C.3
-
6
-
-
0034712536
-
Irinotecan combined with fluorouracil compared with fluorouracil alone. as first-line treatment for metastatic colorectal cancer: A multicentre randomised trial
-
Douillard JY, Cunningham D, Roth AD, et al: Irinotecan combined with fluorouracil compared with fluorouracil alone as first-line treatment for metastatic colorectal cancer: A multicentrerandomised trial. Lancet 355:1041-1047, 2000 (Pubitemid 30162806)
-
(2000)
Lancet
, vol.355
, Issue.9209
, pp. 1041-1047
-
-
Douillard, J.Y.1
Cunningham, D.2
Roth, A.D.3
Navarro, M.4
James, R.D.5
Karasek, P.6
Jandik, P.7
Iveson, T.8
Carmichael, J.9
Alakl, M.10
Gruia, G.11
Awad, L.12
Rougier, P.13
-
7
-
-
1842569206
-
A randomized controlled trial of fluorouracil plus leucovorin, irinotecan, and oxaliplatin combinations in patients with previously untreated metastatic colorectal cancer
-
DOI 10.1200/JCO.2004.09.046
-
Goldberg RM, Sargent DJ, Morton RF, et al: A randomized controlled trial of fluorouracil plus leucovorin, irinotecan, and oxaliplatin combinations in patients with previously untreated metastatic colorectal cancer. J Clin Oncol 22:23-30, 2004 (Pubitemid 41095110)
-
(2004)
Journal of Clinical Oncology
, vol.22
, Issue.1
, pp. 23-30
-
-
Goldberg, R.M.1
Sargent, D.J.2
Morton, R.F.3
Fuchs, C.S.4
Ramanathan, R.K.5
Williamson, S.K.6
Findlay, B.P.7
Pitot, H.C.8
Alberts, S.R.9
-
8
-
-
1342290189
-
FOLFIRI followed by FOLFOX6 or the reverse sequence in advanced colorectal cancer: A randomized GERCOR study
-
DOI 10.1200/JCO.2004.05.113
-
Tournigand C, André T, Achille E, et al: FOLFIRI followed by FOLFOX6 or the reverse sequence in advanced colorectal cancer: A randomized GERCOR study. J Clin Oncol 22:229-237, 2004 (Pubitemid 41095086)
-
(2004)
Journal of Clinical Oncology
, vol.22
, Issue.2
, pp. 229-237
-
-
Tournigand, C.1
Andre, T.2
Achille, E.3
Lledo, G.4
Flesh, M.5
Mery-Mignard, D.6
Quinaux, E.7
Couteau, C.8
Buyse, M.9
Ganem, G.10
Landi, B.11
Colin, P.12
Louvet, C.13
De Gramont, A.14
-
9
-
-
77955266489
-
Cetuximab plus FOLFIRI: Final data from the CRYSTAL study on the association of KRAS and BRAF biomarker status with treatment outcome
-
abstr 3570
-
Van Cutsem E, Lang I, Folprecht G, et al: Cetuximab plus FOLFIRI: Final data from the CRYSTAL study on the association of KRAS and BRAF biomarker status with treatment outcome. J Clin Oncol 28:15s, 2010 (suppl; abstr 3570)
-
(2010)
J Clin Oncol
, vol.28
, Issue.SUPPL.
-
-
Van Cutsem, E.1
Lang, I.2
Folprecht, G.3
-
10
-
-
78149250536
-
Randomized, phase III trial of panitumumab with infusional fluorouracil, leucovorin, and oxaliplatin (FOLFOX4) versus FOLFOX4 alone as first-line treatment in patients with previously untreated metastatic colorectal cancer: The PRIME study
-
Douillard JY, Siena S, Cassidy J, et al: Randomized, phase III trial of panitumumab with infusional fluorouracil, leucovorin, and oxaliplatin (FOLFOX4) versus FOLFOX4 alone as first-line treatment in patients with previously untreated metastatic colorectal cancer: The PRIME study. J Clin Oncol 28:4697-4705, 2010
-
(2010)
J Clin Oncol
, vol.28
, pp. 4697-4705
-
-
Douillard, J.Y.1
Siena, S.2
Cassidy, J.3
-
11
-
-
33745904121
-
Estimating costs of care for patients with newly diagnosed metastatic colorectal cancer
-
Paramore LC, Thomas SK, Knopf KB, et al: Estimating costs of care for patients with newly diagnosed metastatic colorectal cancer. Clin Colorectal Cancer 6:52-58, 2006 (Pubitemid 44044002)
-
(2006)
Clinical Colorectal Cancer
, vol.6
, Issue.1
, pp. 52-58
-
-
Paramore, L.C.1
Thomas, S.K.2
Knopf, K.B.3
Cragin, L.S.4
Fraeman, K.H.5
-
12
-
-
58849160546
-
Lifetime and treatment-phase costs associated with colorectal cancer: Evidence from SEER-Medicare data
-
Lang K, Lines LM, Lee DW, et al: Lifetime and treatment-phase costs associated with colorectal cancer: Evidence from SEER-Medicare data. Clin Gastroenterol Hepatol 7:198-204, 2009
-
(2009)
Clin Gastroenterol Hepatol
, vol.7
, pp. 198-204
-
-
Lang, K.1
Lines, L.M.2
Lee, D.W.3
-
13
-
-
79952419581
-
Systemic therapy for metastatic colorectal cancer: Patterns of chemotherapy and biologic therapy use in US medical oncology practice
-
Hess GP, Wang PF, Quach D, et al: Systemic therapy for metastatic colorectal cancer: Patterns of chemotherapy and biologic therapy use in US medical oncology practice. J Oncol Pract 6:301-307, 2010
-
(2010)
J Oncol Pract
, vol.6
, pp. 301-307
-
-
Hess, G.P.1
Wang, P.F.2
Quach, D.3
-
14
-
-
78650320091
-
Treatment patterns and metastasectomy among mCRC patients receiving chemotherapy and biologics
-
Song X, Zhao Z, Barber B, et al: Treatment patterns and metastasectomy among mCRC patients receiving chemotherapy and biologics. Curr Med Res Opin 27:123-130, 2011
-
(2011)
Curr Med Res Opin
, vol.27
, pp. 123-130
-
-
Song, X.1
Zhao, Z.2
Barber, B.3
-
15
-
-
9444223856
-
End-stage renal disease-associated managed care costs among patients with and without diabetes
-
DOI 10.2337/diacare.27.12.2829
-
Joyce AT, Iacoviello JM, Nag S, et al: End-stage renal disease-associated managed care costs among patients with and without diabetes. Diabetes Care 27:2829-2835, 2004 (Pubitemid 39565045)
-
(2004)
Diabetes Care
, vol.27
, Issue.12
, pp. 2829-2835
-
-
Joyce, A.T.1
Iacoviello, J.M.2
Nag, S.3
Sajjan, S.4
Jilinskaia, E.5
Throop, D.6
Pedan, A.7
Ollendorf, D.A.8
Alexander, C.M.9
-
16
-
-
0942279579
-
Cost of illness associated with metastatic breast cancer
-
DOI 10.1023/B:BREA.0000010689.55559.06
-
Rao S, Kubisiak J, Gilden D: Cost of illness associated with metastatic breast cancer. Breast Cancer Res Treat 83:25-32, 2004 (Pubitemid 38141890)
-
(2004)
Breast Cancer Research and Treatment
, vol.83
, Issue.1
, pp. 25-32
-
-
Rao, S.1
Kubisiak, J.2
Gilden, D.3
-
17
-
-
0026639706
-
Adapting a clinical comorbidity index for use with ICD-9-Cm administrative databases
-
Deyo RA, Cherkin DC, Ciol MA: Adapting a clinical comorbidity index for use with ICD-9-Cm administrative databases. J Clin Epidemiol 45:613-619, 1992
-
(1992)
J Clin Epidemiol
, vol.45
, pp. 613-619
-
-
Deyo, R.A.1
Cherkin, D.C.2
Ciol, M.A.3
-
18
-
-
0032778289
-
Using healthcare claims data for outcomes research and pharmacoeconomic analyses
-
DOI 10.2165/00019053-199916010-00001
-
Birnbaum HG, Cremieux PY, Greenberg PE, et al: Using healthcare claims data for outcomes research and pharmacoeconomic analyses. Pharmacoeconomics 16:1-8, 1999 (Pubitemid 29330467)
-
(1999)
PharmacoEconomics
, vol.16
, Issue.1
, pp. 1-8
-
-
Birnbaum, H.G.1
Cremieux, P.Y.2
Greenberg, P.E.3
LeLorier, J.4
Ostrander, J.5
Venditti, L.6
-
19
-
-
84964137668
-
The surgical pathology of rectal cancer: President's address
-
Dukes CE: The surgical pathology of rectal cancer: President's address. Proc R Soc Med 37:131-144, 1944
-
(1944)
Proc R Soc Med
, vol.37
, pp. 131-144
-
-
Dukes, C.E.1
|